Puma Biotechnology (PBYI) Short term Debt (2020 - 2026)

Puma Biotechnology has reported Short term Debt for 6 years, with the latest figure at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt fell 75.11% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (down 75.11% YoY), and the FY2025 full-year result was $22.5 million, down 50.31% from the prior year.
• Short term Debt for Q1 2026 stood at $11.3 million, down from $22.5 million in the prior quarter.
• The five-year high for Short term Debt was $45.3 million in Q1 2024, with the low at $11.3 million in Q1 2026.
• Historically, Short term Debt has averaged $33.0 million across 4 years, with a median of $34.0 million in 2023.
• Annual changes were most pronounced in 2024 — Short term Debt jumped 300.01% — and 2026, when it tumbled 75.11%.
• Puma Biotechnology's Short term Debt stood at $34.0 million in 2023, then surged by 33.33% to $45.3 million in 2024, then plunged by 50.31% to $22.5 million in 2025, then tumbled by 49.9% to $11.3 million in 2026.
• The last three Short term Debt figures came in at $11.3 million (Q1 2026), $22.5 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.